These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2074045)

  • 1. Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin.
    Villani F; Galimberti M; Monti E; Piccinini F; Lanza E; Rozza A; Favalli L; Poggi P; Zunino F
    Free Radic Res Commun; 1990; 11(1-3):145-51. PubMed ID: 2074045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione.
    Villani F; Galimberti M; Zunino F; Monti E; Rozza A; Lanza E; Favalli L; Poggi P
    Cancer Chemother Pharmacol; 1991; 28(5):365-9. PubMed ID: 1914080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of flunarizine on the delayed cardiotoxicity of doxorubicin in rats.
    Villani F; Galimberti M; Monti E; Piccinini F; Poggi P; Lanza E; Rozza A; Favalli L
    Pharmacol Res; 1991 Feb; 23(2):195-202. PubMed ID: 2062794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione.
    Yoda Y; Nakazawa M; Abe T; Kawakami Z
    Cancer Res; 1986 May; 46(5):2551-6. PubMed ID: 3697994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia as a risk factor for doxorubicin-induced cardiotoxicity: a NMR evaluation.
    Bradamante S; Monti E; Paracchini L; Perletti G
    Biochem Biophys Res Commun; 1989 Sep; 163(2):682-8. PubMed ID: 2783116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529.
    Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M
    Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase].
    Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P
    G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity and antitumor activity of a copper(II)-doxorubicin chelate.
    Monti E; Paracchini L; Piccinini F; Malatesta V; Morazzoni F; Supino R
    Cancer Chemother Pharmacol; 1990; 25(5):333-6. PubMed ID: 2155062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats.
    Fadillioğlu E; Erdoğan H; Söğüt S; Kuku I
    J Appl Toxicol; 2003; 23(1):71-4. PubMed ID: 12518339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres.
    Venditti P; Balestrieri M; De Leo T; Di Meo S
    Cardiovasc Res; 1998 Jun; 38(3):695-702. PubMed ID: 9747437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin.
    Danesi R; Bernardini N; Agen C; Costa M; Zaccaro L; Pieracci D; Malvaldi G; Del Tacca M
    Cancer Chemother Pharmacol; 1992; 29(4):261-5. PubMed ID: 1472260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin cardiotoxicity: contractile changes after long-term treatment in the rat.
    Jensen RA
    J Pharmacol Exp Ther; 1986 Jan; 236(1):197-203. PubMed ID: 3941392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity and cytotoxicity of the anthracycline analog 4'-deoxy-4'-iodo-doxorubicin.
    Danesi R; Bernardini N; Agen C; Costa M; Macchiarini P; Della Torre P; Del Tacca M
    Toxicology; 1991; 70(2):243-53. PubMed ID: 1763418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity.
    Miyagawa M; Tanada S; Hamamoto K
    Eur J Nucl Med; 1991; 18(5):332-8. PubMed ID: 1834467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of doxorubicin-induced toxicity in the intact Lou/M Wsl rat and in isolated heart preparations.
    de Wildt DJ; de Jong Y; Hillen FC; Steerenberg PA; van Hoesel QG
    J Pharmacol Exp Ther; 1985 Oct; 235(1):234-40. PubMed ID: 4045723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of spin-trapping agents on adriamycin-induced cardiotoxicity in isolated rat atria.
    Monti E; Paracchini L; Perletti G; Piccinini F
    Free Radic Res Commun; 1991; 14(1):41-5. PubMed ID: 2022345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
    Herman EH; Zhang J; Ferrans VJ
    Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trifluoperazine does not affect doxorubicin cardiotoxicity in the rat.
    Villani F; Monti E; Piccinini F; Favalli L; Rozza Dionigi A; Lanza E; Poggi P
    Anticancer Res; 1988; 8(4):659-63. PubMed ID: 3178155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between cytocidal activity and glutathione-S-transferase inhibition using doxorubicin coupled to stereoisomers of glutathione with different substrate specificity.
    Hashizume Y; Asakura T; Oikawa T; Yamauchi T; Soda K; Ohkawa K
    Anticancer Drugs; 2001 Jul; 12(6):549-54. PubMed ID: 11460002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetylcysteine reverses cardiac myocyte dysfunction in HIV-Tat proteinopathy.
    Chen F; Lewis W; Hollander JM; Baseler W; Finkel MS
    J Appl Physiol (1985); 2012 Jul; 113(1):105-13. PubMed ID: 22556393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.